Get the Stockscreener App
20.08
6.47%
-1.39
After Hours:
19.62
-0.46
-2.29%
Cue Biopharma Inc stock is traded at $20.08, with a volume of 68,093.
It is down -6.47% in the last 24 hours and up +13.48% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$21.47
Open:
$21.47
24h Volume:
68,093
Relative Volume:
0.10
Market Cap:
$81.24M
Revenue:
$32.73M
Net Income/Loss:
$-19.52M
P/E Ratio:
-3.6327
EPS:
-5.5275
Net Cash Flow:
$-24.61M
1W Performance:
-1.08%
1M Performance:
+13.48%
6M Performance:
+6.96%
1Y Performance:
+1.20%
1-Day Range:
$19.76
$22.51
1-Week Range:
$18.20
$22.51
52-Week Range:
$4.971
$41.42
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
20.08 | 86.86M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma Analyst Ratings and Price Targets | NASDAQ:CUE - Benzinga
Cue Biopharma Inc stock (US22966J1060): capital raise, pipeline focus and conference spotlight - AD HOC NEWS
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Cue Biopharma CEO to present at Jefferies healthcare conference in NYC - Stock Titan
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference | Associated Press | syndication news - Enidnews.com
Major dilution on table as Cue Biopharma (CUE) asks holders to OK warrants and 2026 plan - Stock Titan
MSN Money - MSN
Cue Biopharma Company Profile & Introduction - Moomoo
Cue Biopharma Inc stock (US22966J1060): cancer immunotherapy hopes meet volatile share price - AD HOC NEWS
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments - The Manila Times
Cue Biopharma earnings beat by $2.22, revenue topped estimates - Investing.com Canada
Cue Biopharma receives $7.5M milestone payment from Boehringer Ingelheim - MSN
Cue Biopharma reports Q1 loss, secures $30M financing - Investing.com UK
CUE Financials: Income Statement, Balance Sheet & Cash Flow | Cue Biopharma Inc - Stock Titan
Cue Biopharma reports Q1 loss, secures $30M financing By Investing.com - Investing.com Nigeria
Cue Biopharma (CUE) boosts Q1 revenue, raises $30M and trims net loss - Stock Titan
[10-Q] Cue Biopharma, Inc. Quarterly Earnings Report - Stock Titan
Press Release: Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments - Moomoo
Cue Biopharma stock (US22966J1060): Analysts set $4 average price target - AD HOC NEWS
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cue Biopharma, Inc. announced that it has received $29.999992 million in funding - marketscreener.com
CUE Stock Chart | CUE BIOPHARMA INC (NASDAQ:CUE) - ChartMill
Cue Biopharma (NASDAQ: CUE) asks shareholders to approve 4.64M warrant shares, 2026 equity plan - Stock Titan
TradingKey - TradingKey
Wall Street Zen Upgrades Cue Biopharma (NASDAQ:CUE) to Strong-Buy - MarketBeat
What's behind the drop in Cue Biopharma stock today? - MSN
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cue Biopharma Inc. R (1UC0.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cue Biopharma Grants Inducement Equity Awards to New Executive and Employees - Quiver Quantitative
New Cue Biopharma CEO gets 655,074-share option and 327,537 stock units - Stock Titan
Cue Biopharma, Inc. Common Stock (CUE) Stock Price Today & Analysis - Gotrade
Cue Biopharma (CUE) CEO Shao-Lee Lin submits initial Form 3 - Stock Titan
Cue Biopharma (CUE) CEO granted 327,537 shares and 655,074 options - Stock Titan
Number of shareholders of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Number of shareholders of Cue Biopharma, Inc. – DUS:1UC0 - TradingView
Cue Biopharma, Inc. Dividends – DUS:1UC0 - TradingView
Cue Biopharma(CUE) Stock Options Chain | Quotes & News - Moomoo
Cue Biopharma (CUE) price target increased by 2,900.00% to 122.40 - MSN
Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):